Market Cap 23.65B
Revenue (ttm) 3.81B
Net Income (ttm) -644.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 318.72
Profit Margin -16.92%
Debt to Equity Ratio 0.05
Volume 189,200
Avg Vol 468,388
Day's Range N/A - N/A
Shares Out 99.25M
Stochastic %K 82%
Beta 0.35
Analysts Strong Sell
Price Target $321.39

Company Profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multic...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 61 685 19 00
Address:
94 Aeschengraben 27, Basel, Switzerland
Meril_Knoxville
Meril_Knoxville Jul. 29 at 9:38 AM
0 · Reply
PrivateTrading
PrivateTrading Jul. 23 at 8:17 PM
$ONC An analyst from JPMorgan maintained BeOne Medicines at ’overweight’ with a price target of $425.00 from a prior price target of $415.00.
0 · Reply
BixbyKnolls
BixbyKnolls Jul. 23 at 6:48 PM
$IBRX I tersting build out in Production USA- a big build but only adding 135 employees? $ONC - Collaboration on one trial that I know of.. Probably other projects..
0 · Reply
PrivateTrading
PrivateTrading Jul. 22 at 11:46 AM
$ONC An undervalued company. Market cap to Sales ratio. Sales growth. Sonrotoclax + Brukinsa will be a formidable fixed duration solution. BGB-16673 as a 2L would be a huge asset. However, I think the FDA would approve it as a 3L initially.
0 · Reply
Estimize
Estimize Jul. 20 at 11:01 AM
Wall St is expecting 1.57 EPS for $ONC Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
MaverikIT
MaverikIT Jul. 15 at 3:49 PM
$BABA +6.32 - some saying 'uninvestable' for china - haha $SE $ONC @G_R_
0 · Reply
notreload_ai
notreload_ai Jul. 13 at 9:41 AM
Jefferies upgrades $ONC from Hold to Buy and raises price target to $380, implying 27% upside. Strong Brukinsa outlook and solid tumor pipeline drive bullish view. https://notreload.xyz/xy/analyst-upgrade-boosts-onc-as-brukinsa-outlook-strengthens/
0 · Reply
Pika_Capital
Pika_Capital Jul. 6 at 3:50 PM
$ONC loaded heavily under $300. One of the most mispriced bios out there
1 · Reply
Estimize
Estimize Jul. 6 at 11:03 AM
Wall St is expecting 1.65 EPS for $ONC Q2 [Reporting 08/21 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
PrivateTrading
PrivateTrading Jun. 26 at 8:02 PM
$ONC On June 26, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment.
0 · Reply
Latest News on ONC
BeOne Medicines to invest $300M in New Jersey R&D center

2026-07-23T10:21:26.000Z - 7 days ago

BeOne Medicines to invest $300M in New Jersey R&D center


BeOne Medicines upgraded to Buy from Hold at Jefferies

2026-07-13T01:05:04.000Z - 18 days ago

BeOne Medicines upgraded to Buy from Hold at Jefferies


BeOne Medicines AG Transcript: Study update

Jun 1, 2026, 8:00 PM EDT - 2 months ago

BeOne Medicines AG Transcript: Study update


BeOne Medicines AG Press release: Study update

Jun 1, 2026, 8:00 PM EDT - 2 months ago

BeOne Medicines AG Press release: Study update


BeOne Medicines AG Slides: Study update

Jun 1, 2026, 8:00 PM EDT - 2 months ago

BeOne Medicines AG Slides: Study update


BeOne Medicines’ Beqalzi granted accelerated approval by FDA

2026-05-13T19:42:59.000Z - 2 months ago

BeOne Medicines’ Beqalzi granted accelerated approval by FDA


US FDA approves BeOne's drug for a type of blood cancer

May 13, 2026, 1:34 PM EDT - 2 months ago

US FDA approves BeOne's drug for a type of blood cancer

ONC


BeOne Medicines AG Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Earnings Call Transcript: Q1 2026


BeOne Medicines AG Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Earnings release: Q1 2026


BeOne Medicines AG Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Quarterly report: Q1 2026


BeOne Medicines AG Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Slides: Q1 2026


BeOne Medicines initiated with an Overweight at Wells Fargo

2026-05-04T09:10:32.000Z - 3 months ago

BeOne Medicines initiated with an Overweight at Wells Fargo


BeOne Medicines AG Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Proxy statement: Proxy filing


BeOne Medicines AG Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Proxy statement: Proxy filing


BeOne Medicines AG Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

BeOne Medicines AG Proxy statement: Proxy filing


BeOne Medicines AG Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 5 months ago

BeOne Medicines AG Earnings Call Transcript: Q4 2025


BeOne Medicines AG Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 5 months ago

BeOne Medicines AG Annual report: Q4 2025


BeOne Medicines AG Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 5 months ago

BeOne Medicines AG Earnings release: Q4 2025


BeOne Medicines AG Slides: Q4 2025

Feb 26, 2026, 8:00 AM EST - 5 months ago

BeOne Medicines AG Slides: Q4 2025


BeOne Medicines to Present at Upcoming Investor Conferences

Feb 17, 2026, 6:00 AM EST - 5 months ago

BeOne Medicines to Present at Upcoming Investor Conferences

ONC


Prediction: These 3 Stocks Will Crush the Market in 2026

Mon, 16 Feb 2026 12:45:00 -0500 - 5 months ago

Prediction: These 3 Stocks Will Crush the Market in 2026


3 Stocks to Buy in February

Mon, 02 Feb 2026 02:50:00 -0500 - 6 months ago

3 Stocks to Buy in February


BeOne Medicines AG Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

BeOne Medicines AG Earnings Call Transcript: Q3 2025


BeOne Medicines AG Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

BeOne Medicines AG Quarterly report: Q3 2025


BeOne Medicines AG Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

BeOne Medicines AG Earnings release: Q3 2025


BeOne Medicines AG Slides: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

BeOne Medicines AG Slides: Q3 2025


BeOne Medicines AG Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Earnings Call Transcript: Q2 2025


BeOne Medicines AG Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Quarterly report: Q2 2025


BeOne Medicines AG Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Earnings release: Q2 2025


BeOne Medicines AG Slides: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeOne Medicines AG Slides: Q2 2025


BeOne Medicines AG Transcript: Status Update

Jun 26, 2025, 8:30 AM EDT - 1 year ago

BeOne Medicines AG Transcript: Status Update


BeOne Medicines AG Press release: Status Update

Jun 26, 2025, 8:30 AM EDT - 1 year ago

BeOne Medicines AG Press release: Status Update


BeOne Medicines AG Slides: Status Update

Jun 26, 2025, 8:30 AM EDT - 1 year ago

BeOne Medicines AG Slides: Status Update


Meril_Knoxville
Meril_Knoxville Jul. 29 at 9:38 AM
0 · Reply
PrivateTrading
PrivateTrading Jul. 23 at 8:17 PM
$ONC An analyst from JPMorgan maintained BeOne Medicines at ’overweight’ with a price target of $425.00 from a prior price target of $415.00.
0 · Reply
BixbyKnolls
BixbyKnolls Jul. 23 at 6:48 PM
$IBRX I tersting build out in Production USA- a big build but only adding 135 employees? $ONC - Collaboration on one trial that I know of.. Probably other projects..
0 · Reply
PrivateTrading
PrivateTrading Jul. 22 at 11:46 AM
$ONC An undervalued company. Market cap to Sales ratio. Sales growth. Sonrotoclax + Brukinsa will be a formidable fixed duration solution. BGB-16673 as a 2L would be a huge asset. However, I think the FDA would approve it as a 3L initially.
0 · Reply
Estimize
Estimize Jul. 20 at 11:01 AM
Wall St is expecting 1.57 EPS for $ONC Q2 [Reporting 08/05 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
MaverikIT
MaverikIT Jul. 15 at 3:49 PM
$BABA +6.32 - some saying 'uninvestable' for china - haha $SE $ONC @G_R_
0 · Reply
notreload_ai
notreload_ai Jul. 13 at 9:41 AM
Jefferies upgrades $ONC from Hold to Buy and raises price target to $380, implying 27% upside. Strong Brukinsa outlook and solid tumor pipeline drive bullish view. https://notreload.xyz/xy/analyst-upgrade-boosts-onc-as-brukinsa-outlook-strengthens/
0 · Reply
Pika_Capital
Pika_Capital Jul. 6 at 3:50 PM
$ONC loaded heavily under $300. One of the most mispriced bios out there
1 · Reply
Estimize
Estimize Jul. 6 at 11:03 AM
Wall St is expecting 1.65 EPS for $ONC Q2 [Reporting 08/21 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
PrivateTrading
PrivateTrading Jun. 26 at 8:02 PM
$ONC On June 26, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment.
0 · Reply
Estimize
Estimize Jun. 22 at 11:04 AM
Wall St is expecting 1.65 EPS for $ONC Q2 [Reporting 08/21 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 21 at 3:13 PM
$ONC BeOne Medicines AG (ONC) has a massive $32.74 billion market capitalization, strong gross margins, and several cancer therapies targeting major unmet medical needs. Analysts remain bullish, but is this healthcare stock still flying under the radar for long-term investors? https://biotechhealthx.com/biotech-news/is-beone-medicines-onc-a-smart-biotech-stock-to-watch-for-long-term-growth/
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 21 at 10:05 AM
$ALNY $ONC $BSX $PODD $RYTM Wall Street analysts are spotting major upside in these 10 promising healthcare stocks, including biotech, cancer treatment, diabetes technology, rare disease, and medical device names that could still have serious room to run. https://biotechhealthx.com/biotech-news/top-10-healthcare-stocks-that-could-turn-a-1000-investment-into-something-bigger/
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 18 at 7:33 AM
$ONC holy hell, zbeigene is still in business? And trading at a 60 p/e? Can’t short this and other certain biotech stocks enough @Shortseller $GSK bought $NUVL for a reason. BeOne? beigene? Be Gone 😂 s
1 · Reply
PrivateTrading
PrivateTrading Jun. 12 at 8:05 PM
$ONC Recent share price weakness may be attributed to RSUs that were exercised by executives at the company.
0 · Reply
PrivateTrading
PrivateTrading Jun. 11 at 3:29 PM
$ONC The company has plenty of cash The share price is low Opportunity for the company to support the stock Q. Given that the FDA approved Calquence + venclexta fixed duration in Feb. 2026, why is Brukinsa + Sonrotoclax fixed duration two years behind the competitor?
0 · Reply
DaSqueeza
DaSqueeza Jun. 8 at 7:37 PM
$ONC is also 20x more expensive than $NRIX
1 · Reply
MaxDanger
MaxDanger Jun. 8 at 7:27 PM
$NRIX I like this deal with $RHHBY. It gives the company over a billion in cash, significantly reduces its burn rate by via shared development expenses with roche. Allows them to put money into other assets and speed up development of those products. This is a game changer for the company, removes the risk of dilution for years to come, and increases the speed of development for the rest of their portfolio. $ONC is a bit ahead of them in the degrader space but this deal will level the playing field and allow for additional trials. The only surprise here is that it wasn’t a deal with a $AZN.
0 · Reply
Estimize
Estimize Jun. 8 at 11:03 AM
Wall St is expecting 1.65 EPS for $ONC Q2 [Reporting 08/21 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
Pika_Capital
Pika_Capital Jun. 5 at 2:14 PM
$ONC I'm buying more here
0 · Reply
MarketBeat
MarketBeat Jun. 2 at 6:11 AM
https://marketbeat.com/a/8686887/ $ONC BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 2 at 4:07 AM
$ONC Current Stock Price: $279.79 Contracts to trade: $280.0 ONC Jun 18 2026 Call Entry: $8.90 Exit: $14.19 ROI: 59% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply